Glucan in clinical trials

Abstract

Submit Manuscript | http://medcraveonline.com III clinical trial evaluating the combination therapy of Imprime PGGTM and ErbituxTM in colorectal cancer patients. This study is currently enrolling up to 795 patients and will be conducted at 50 locations worldwide, including the U.S, France and Germany. Results achieved so far are highly promising showing the response rate for patients receiving glucan nearly doubled and median progression-free survival time increased 41%. In addition, Biothera announced that Imprime PGGTM had achieved significant results in meeting endpoint results in the Phase IIb NSCLC clinical trial. Patients in this trial had an objective response rate more than double compared to the control group. In the biomarkerpositive group, the results were even better. In case of chronic lymphocytic leukemia, a high number of patients with a complete response after Imprime and antibody combination is extremely impressive. It is even more impressive when we remember that today most cancer drugs have a response rate well below 40%.